Researchers at Northeast Georgia Medical Center (NGMC) Gainesville’s Level I trauma center are participating in an international clinical trial to study how a device could increase trauma patients’ chances of survival. NGMC Gainesville was chosen among eight leading Level I trauma centers across the United States and Canada.
The trauma team at NGMC Gainesville already performs partial resuscitative balloon occlusion of the aorta – also known as Partial REBOA –to help stop a patient’s internal bleeding through a device called pREBOA-PRO. Now the team will participate in the clinical trial, called the PROMPT (Partial REBOA Outcomes Multicenter ProspecTive) Study, to share data about the use of the device.
“No one should bleed to death – and the sooner we can stop the bleeding, the better,” said Matthew Vassy, MD, medical director of trauma at NGMC. “Time is of the essence for trauma patients, and this PROMPT study should give us compelling data to improve how we save lives.”
The PROMPT study will provide the trauma community with in-depth clinical data by enrolling 340 patients in two years across all eight selected centers. NGMC patients who match the study criteria will be automatically enrolled in the study this spring. Learn more about NGMC’s trauma program at nghs.com/trauma.
About Northeast Georgia Medical Center
Since 1951, Northeast Georgia Medical Center (NGMC) has been on a mission of improving the health of our community in all we do. With hospitals located in Gainesville, Braselton, Winder and Dahlonega, the four NGMC campuses have a total of more than 750 beds and more than 1,200 medical staff members representing more than 60 specialties. NGMC is part of Northeast Georgia Health System, a non-profit that cares for more than one million people across more than 19 counties. Learn more at www.nghs.com.
About Prytime Medical, Inc.
The pREBOA-PRO device is a product of Prytime Medical Inc, The REBOA Company™, a leading innovator and global provider of lifesaving REBOA products. Prytime was selected by the U.S. Army Medical Research and Development Command to receive nearly $6 million from the U.S. Department of Defense awarded through the Medical Technology Enterprise Consortium.
About U.S. Army Medical Research & Development Command
The U.S. Army Medical Research and Development Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense. https://mrdc.amedd.army.mil/
The Medical Technology Enterprise Consortium is a 501(c)(3) biomedical technology consortium that is internationally-dispersed, collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement with the U.S. Army Medical Research and Development Command. The consortium focuses on the development of medical solutions that protect, treat, and optimize the health and performance of U.S. military personnel and civilians. To find out more about MTEC, visit mtec-sc.org.
Disclaimer: The views expressed in this news release/article are those of the authors and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.